adalimumab,secukinumab,methotrexate
abbvie,amgen,novartis
[' psa', ' ada ', 'ada ']
psa, other lessons learned from trials mtx may be good in early, bio-naive psa il-17i &gt; tnfi for combined outcomes (e.g., acr50 + pasi100) though in h2h study of ada vs sec primary outcome showed no difference #acr22 #reviewcourse 
@bu_bmc_rheum | @rheum_covid @spartan_updates @official_asas | @UWRheum @UWEpidemiology 2020 | @OHSUIMres 2017 | @UTMBhealth 2014 | @UTAustin 2010